<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702167</url>
  </required_header>
  <id_info>
    <org_study_id>16-6252-B</org_study_id>
    <nct_id>NCT02702167</nct_id>
  </id_info>
  <brief_title>High-frequency vs. Low-frequency vs. Sham DMPFC-rTMS for Bulimia and Anorexia Nervosa</brief_title>
  <official_title>The Dorsomedial Prefrontal Cortex as a Target in Treatment-resistant Bulimia Nervosa and Anorexia Nervosa: Investigating Target Engagement, Dosing, Reliability and Duration of Effect Using rTMS, fMRI, and a Sham Controlled Arm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will compare the efficacy and tolerability of 10 Hz vs. 1 Hz vs. sham repetitive
      transcranial magnetic stimulation targeting the dorsomedial prefrontal cortex, delivered once
      daily over 30 days, in patients with a diagnosis of bulimia or anorexia nervosa binge-purge
      subtype. The trial will include structural and functional MRI, and behavioral measures
      obtained before, during, and after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weekly Binge/Purge Frequency on Eating Disorder Examination (EDE)</measure>
    <time_frame>Baseline, after each week of treatment, and 1, 4, 12, and 24 weeks post-treatment</time_frame>
    <description>Outcome measured by a change in weekly binge and purge episodes from baseline to 2 weeks post-treatment. A 50% improvement in the score is considered a response to rTMS. A final score of 0 weekly binges and 0 weekly vomits is categorized as remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eating Disorder Inventory-3</measure>
    <time_frame>Baseline, after each week of treatment, and 1, 4, 12, and 24 weeks post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eating Disorder Examination Questionnaire (EDE-Q)</measure>
    <time_frame>Baseline, after each week of treatment, and 1, 4, 12, and 24 weeks post-treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Resting-state functional MRI</measure>
    <time_frame>1 week pre- and 1 week post-intervention</time_frame>
    <description>10 min resting-state functional MRI acquisition at 3T</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Bulimia Nervosa</condition>
  <condition>Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>High-frequency rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-frequency rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-frequency rTMS</intervention_name>
    <description>10 Hz active stimulation, once daily</description>
    <arm_group_label>High-frequency rTMS</arm_group_label>
    <other_name>Magventure Cool DB80 Active/Placebo Coil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low-frequency rTMS</intervention_name>
    <description>1 Hz active stimulation, once daily</description>
    <arm_group_label>Low-frequency rTMS</arm_group_label>
    <other_name>Magventure Cool DB80 Active/Placebo Coil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham rTMS</intervention_name>
    <description>Sham stimulation, once daily</description>
    <arm_group_label>Sham rTMS</arm_group_label>
    <other_name>Magventure Cool DB80 Active/Placebo Coil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Patient):

          -  Voluntary and Competent to Consent

          -  MINI confirmed Diagnosis of Bulimia Nervosa OR Anorexia Nervosa, Binge/Purge subtype

          -  Outpatient

          -  Between the ages of 18-65

          -  Have had no increase or initiation of any psychotropic medication in the last 4 weeks
             prior to screening

          -  Must adhere to research schedule.

          -  Pass the TMS Safety Screening Questionnaire.

          -  Failed to achieve a clinical response to at least one pharmacotherapy or behavioral
             treatment in the current episode.

        Exclusion Criteria (Patient):

          -  Have a concomitant major unstable medical illness, cardiac pacemaker or implanted
             medical pump

          -  Have active suicidal intent

          -  Are pregnant

          -  Have a lifetime MINI diagnosis of bipolar I or II disorder, schizophrenia,
             schizoaffective disorder, schizophreniform, delusional disorder, or current psychotic
             symptoms

          -  Have a MINI diagnosis of obsessive-compulsive disorder, post-traumatic stress disorder
             (current or within the last year), anxiety disorder (generalized anxiety disorder,
             social anxiety disorder, panic disorder), or dysthymia assessed by a study
             investigator to be primary and causing greater impairment than the ED

          -  Have received rTMS for any previous indication due to the potential compromise of
             subject blinding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Downar, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Blake Woodside, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eileen Lam</last_name>
    <phone>416-603-5800</phone>
    <phone_ext>5494</phone_ext>
    <email>eileen.lam@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katie Dunlop</last_name>
    <phone>416-603-5667</phone>
    <email>katie.dunlop@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Lam</last_name>
      <phone>416-603-5667</phone>
      <email>eileen.lam@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Katie Dunlop</last_name>
      <phone>416-603-5667</phone>
      <email>katie.dunlop@uhn.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Downar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Blake Woodside</investigator_full_name>
    <investigator_title>Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>brain stimulation</keyword>
  <keyword>rTMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Bulimia Nervosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

